MIRA Pharmaceuticals (MIRA) Stock: Buy, Sell, or Hold?
MIRA - MIRA Pharmaceuticals, Inc. Common Stock
$0.73
0.01 (0.98%)
▲
5d:
-18.88%
30d:
-14.06%
90d:
-23.54%
WAIT
LOW Confidence
Analysis Updated: Oct 2, 2026 12:00 AM ET
Earnings: Nov 12, 2026
Get Alerted When MIRA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: MIRA is down 18.9% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: MIRA is down 18.9% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: MIRA is currently trading at $0.73, which is considered oversold relative to its 30-day fair value range of $0.74 to $0.86.
Technical Outlook: Technically, MIRA is in a downtrend. Immediate support is located at $0.62, while resistance sits at $0.94.
Market Sentiment: MIRA scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $3.50 (+379.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, MIRA is in a downtrend. Immediate support is located at $0.62, while resistance sits at $0.94.
Market Sentiment: MIRA scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $3.50 (+379.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$0.74 -
$0.86
Company Quality Score
36/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
57.9%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (15/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 379.4% below Wall St target ($3.50)
- WARNING: Composite score 36/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$0.74 -
$0.86
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$0.62
Resistance Level
$0.94
Current Trend
Downtrend
Technical data as of
Oct 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-4.56
Wall Street Target
$3.50
(+379.4%)
Share & Embed Analysis
Last updated: October 03, 2026 1:39 PM ET
Data refreshes hourly during market hours. Next update: 2:39 PM
Data refreshes hourly during market hours. Next update: 2:39 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is MIRA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - General Stocks
Top-rated stocks in Drug Manufacturers - General by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
LLY
Eli Lilly and Company |
STRONG BUY
31 analysts |
$1325 | 48 HOLD |
|
GILD
Gilead Sciences Inc |
BUY
30 analysts |
$159 | 46 HOLD |
|
ABBV
AbbVie Inc |
BUY
28 analysts |
$279 | 57 HOLD |
|
AMGN
Amgen Inc |
HOLD
32 analysts |
$389 | 55 HOLD |
|
BIIB
Biogen Inc |
HOLD
37 analysts |
$238 | 48 HOLD |
